Cultivating the next generation of bioscience entrepreneurs.

A VENTURE INVESTING FOCUS.

Kansas Bioscience Authority invests in agribusiness, animal health, and human health innovations. The team brings deep sector expertise and co-investors together to accelerate bioscience company growth generating results for the entrepreneur, the investor, Kansas and the world.

KBA Logo

Cultivating the next generation of bioscience entrepreneurs.

A VENTURE INVESTING FOCUS.

Kansas Bioscience Authority invests in agribusiness, animal health, and human health innovations. The team brings deep sector expertise and co-investors together to accelerate bioscience company growth generating results for the entrepreneur, the investor, Kansas and the world.

KBA Logo

AGRIBUSINESS

KBA invests in disruptive technological advances in agriculture, plant science and plant-based products that help provide a safe and bountiful food supply to address an ever increasing global food demand.The KBA is also interested in technologies to produce sustainable fuels and chemicals from agricultural products/by products that can replace petrochemical derivatives.

Learn More

ANIMAL HEALTH

Located among the world’s largest concentration of animal health and nutrition companies, KBA invests in production and companion animal health innovations. Disruptive technologies that improve food safety, food production, and bring new tools and therapies to animal health are of particular interest. The KBA looks to human health and other disciplines for novel animal health innovations.

Learn More

HUMAN HEALTH

KBA invests in new medical devices, healthcare IT, and diagnostics that protect and advance human health. KBA looks for investments that will bring these innovations to market in ways that maximize value creation by investing at key value inflection points, such as proof of concept development or early commercial success.

Learn More

AAD Closes $15 Million in Oversubscribed Series C Funding

Advanced Animal Diagnostics (AAD) has announced the close of a $15 million Series C round of equity financing. The financing was co-led by the Kansas Bioscience Authority and Cultivian Sandbox and included Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), Middleland Capital, and existing investors Intersouth Partners, Novartis Venture Funds and private individuals. The investment will allow AAD to accelerate the commercialization of its current product offering, QScout® MLD (milk leukocyte differential) test, while also expanding the company’s product line.  AAD plans to conduct product development research with the Kansas State Veterinary Diagnostics Lab in Manhattan, KS, is working with a Lenexa manufacturer to make components of the Qscout Lab, and plans to establish a sales office in Western Kansas to support its current dairy product and future feedlot products.

Learn More